Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

BPC-157 Nasal Spray vs. Injections | Comprehensive Comparison

Curious about BPC-157 nasal spray vs. injections? If so, this guide has researchers covered. Below, our experts detail all the key info on BPC-157 nasal spray, injections and oral capsules, including… What is BPC-157? Benefits of BPC-157 nasal spray BPC-157 na

Curious about BPC-157 nasal spray vs. injections?

If so, this guide has researchers covered.

Below, our experts detail all the key info on BPC-157 nasal spray, injections and oral capsules, including…

What is BPC-157?

Benefits of BPC-157 nasal spray

BPC-157 nasal spray vs. injections

BPC-157 nasal spray vs. capsules

For researchers interested in BPC-157, this is the definitive review of the optimal routes of administration. We also detail BPC-157 research applications, side effects, and more.

Lastly, we will give our highest recommendation for researchers looking to source the best BPC-157 the web has to offer.

Buy BPC-157 + TB-500 Nasal Spray Blend from our top-rated vendor...

Disclaimer: Peptides.org contains information about products that are intended for laboratory and research use only, unless otherwise explicitly stated. This information, including any referenced scientific or clinical research, is made available for educational purposes only. Likewise, any published information relative to the dosing and administration of reference materials is made available strictly for reference and shall not be construed to encourage the self-administration or any human use of said reference materials. Peptides.org makes every effort to ensure that any information it shares complies with national and international standards for clinical trial information and is committed to the timely disclosure of the design and results of all interventional clinical studies for innovative treatments publicly available or that may be made available. However, research is not considered conclusive. Peptides.org makes no claims that any products referenced can cure, treat or prevent any conditions, including any conditions referenced on its website or in print materials.

What is BPC-157?

BPC-157 (Body Protection Compound-157), otherwise known as bepecin, is a synthetic peptide that is under clinical investigation for numerous therapeutic applications.

A derivative of the naturally occurring gastric protein called Body Protection Compound (BPC), BPC-157 is classed as a pentadecapeptide, composed of 15 amino acids. Endogenous BPC is produced in the gastrointestinal tract and is essential to proper digestive function. It maintains the lining of the GI tract, healing and preventing lesions while combating oxidative stress. This regenerative peptide is shown to promote angiogenesis, cellular repair, tissue growth, and improved inflammatory response [1, 2, 3].

Therapeutic Considerations

BPC-157 is more stable than its parent compound, and studies indicate that it does not require a carrier agent to elicit systemic effects. Like endogenous BPC, it exhibits powerful cytoprotective properties, fortifying, protecting, and healing the lining of the GI tract. Research shows that its angiogenic and anti-inflammatory benefits may extend beyond the digestive system even in small doses.

In stimulating vascular growth and fibroblast proliferation, BPC-157 is linked with faster injury and wound healing in multiple tissue types. These include hepatic and nervous tissues, as well as muscle, bone, and tendon. BPC-157 is further shown to have powerful anti-inflammatory effects throughout the GI tract and systemically, lending it potential in the treatment of inflammatory and metabolic diseases [2, 3, 4, 5, 6].

Clinical Background

BPC-157 was introduced in 1993 and initially studied as a potential treatment for inflammatory bowel disease due to its anti-ulcer effects. Although it entered phase I clinical trials in this regard, BPC-157 is not certified by the US Food and Drug Administration (FDA) for medical use. As such, substantial data on BPC-157 administration in humans is lacking. However, research to date suggests that BPC-157 is non-toxic and well-tolerated when properly handled in qualified settings [1–7].

Routes of Administration

Like many research peptides, injection of BPC-157 has historically been the favored route of administration due to the compound’s instability and consequent low oral bioavailability. However, a highly stable form of BPC-157 called BPC-157 arginate has recently been developed, exhibiting oral bioavailability of over 90%. Given the peptide’s notable gastroprotective effects, it may be well suited to this novel capsular form [8, 9, 10].

BPC-157 has also been applied topically in several animal studies into its wound-healing capabilities. Although research on intranasal administration of BPC-157 is extremely limited, broad studies on the potential benefits of intranasally administered peptide therapeutics suggest that this may be a beneficial RoA [11, 12].

Nasal formulas from reputable peptide sources have recently become available for researchers to explore this promising means of application, as detailed below.

Overall, BPC-157 currently has four routes of administration available for research:

Injectable

Nasal spray

Oral capsules

Topical

Continue reading to learn more about the benefits of intranasal BPC-157 use, as well as how it compares to oral and parenteral routes.

BPC-157 Nasal Spray | What Researchers MUST Know

Clinical interest in nasal drug delivery has increased in recent years due to its unique advantages in certain therapeutic contexts. Intranasal administration is valued as a non-invasive means of both systemic and local administration with good bioavailability, rapid onset, and targeted effects on the central nervous system [13, 14].

Nasal delivery may be particularly effective in the treatment of neurological diseases due to the direct nose-to-brain pathway. This includes neurodegenerative diseases such as Alzheimer’s, as well as mental health conditions like schizophrenia. However, intranasal administration is also considered an efficient route for systemic effects due to the dense vasculature of the nasal mucosa. Researchers note that intranasal delivery may especially increase the bioavailability of peptide therapeutics and present an appealing alternative to injection [14, 15, 16].

BPC-157 and Nasal Delivery

Despite mounting research on nasal peptide administration, studies on nasal delivery of BPC-157 are lacking. Yet, the few trials to date are promising.

In one study, BPC-157 was shown to reduce brain swelling and inflammation with topical application in rats with superior sagittal thrombosis. Another study on intranasal administration of BPC-157 in rats with rhinitis elicited anti-inflammatory effects in the nasal lining [17, 18].

Given the evidenced benefits of BPC-157 on neurological health, including neuroprotection, neurotransmitter modulation, and the maintenance of systemic homeostasis via the brain-gut axis, it may be particularly suited to nasal administration. As such, leading peptide brands have begun to develop BPC-157 nasal spray formulas, such as Limitless Life' BPC-157/TB-500 Spray, for innovative researchers to enjoy [19, 20].

Next, we will explore how intranasal BPC-157 delivery compares to other common routes of administration.

Comparison | BPC-157 Nasal Spray vs. Injections

Is one method better than another when administering BPC-157? The answer may be complicated, especially depending on the context of the research.

Let’s look at the main factors to consider:

Bioavailability

Traditionally, injection has been considered the most efficient route of administering peptide drugs due to their instability and rapid degradation with oral, topical, and other delivery methods.

BPC-157 has been shown in animal models to adhere to the metabolic process of standard peptide-based drugs, suggesting that injections are the most bioavailable route of delivery. Indeed, studies on BPC-157 to date have more often featured injection rather than nasal delivery [21, 22].

However, emerging research and novel formulations may alter these dynamics. For example, a more stable and highly orally available form of BPC-157 known as BPC157 arginate has recently been developed.

Further, clinicians have only recently begun to consider the unique advantages of nasal administration, spurring the development of pharmaceuticals that are highly bioavailable via the nasal mucosa. Compared with injection, intranasal delivery is favorably recognized as a less invasive method of bypassing the blood-brain barrier [10, 13, 23].

Therapeutic Context

Research findings suggest that the optimal use of BPC-157 is in many cases dependent on the therapeutic target, as different routes of delivery and dosages elicit varying effects.

For gastroprotective benefits, oral delivery may be the best. Meanwhile, as noted above, targeted neurological effects may best be achieved with nasal sprays. In contexts of vascular disease or global effects, injection may remain the preferred method [2, 20, 24, 25].

Additional considerations include the comfort of the subject.

Nasal sprays are less invasive than injections and therefore more suited to regular use. Consequently, this format may be more marketable and thus likely to receive increased development interest and regulatory approval [13].

In short, researchers are strongly encouraged to become familiar with relevant findings on the best handling and administration protocols for specific uses of BPC-157, as optimal delivery methods are subject to change.

Comparison | BPC-157 Nasal Spray vs. Oral Capsules

While nasal sprays evidence substantial utility for targeted neurological effects, when it comes to gastrointestinal benefits, orally delivered BPC-157 capsules may be the best option.

Breakthrough BPC-157 arginate formulas that are highly stable, bioavailable, and long-acting have great therapeutic potential. Like nasal sprays, capsules are non-invasive and appealing for regular use [10, 24, 26].

Many promising recent developments in BPC-157 research are now in capsules format. These unique capsules are made with highly stable and orally effective BPC-157 and additional therapeutic compounds for enhanced benefits.

Here are a few to consider when researcher the BPC-157 peptide:

Repair and Recovery Formula: Stable BPC-157 Arginate, Thymosin Beta-4 Fragment

The star ingredient of this cutting-edge preparation is BPC-157 arginate, exhibiting significantly greater stability and oral activity than the original form, BPC-157 acetate. It is resistant to gastric acids and maintains the therapeutic action of the standard iteration.

This ultra-healing peptide is partnered with a derivative of another potent regenerative peptide called thymosin beta-4 (TB4), also known as TB-500. Featured in a smaller, fragmentary form for easier GI tract absorption, it imparts further anti-inflammatory and immunomodulating benefits for a synergistic healing effect [10, 27, 28, 29].

This formula is sure to be of interest to researchers interested in enhanced injury recovery, as well as addressing symptoms of inflammatory, cardiovascular, and neurological diseases.

Gut Inflammation Formula: Stable BPC-157 Arginate, KPV

This potent formula combines a trio of anti-inflammatory compounds with orally active BPC-157 arginate for focused healing of the gastrointestinal tract. Each one of the naturally-occurring ingredients is shown to combat GI inflammation through distinct mechanisms, eliciting synergistic benefits. KPV and tributyrin partner to regulate damaging cytokines associated with inflammatory bowel disease, while BPC-157 and PEA calm and fortify the GI lining [8, 30, 31, 32].

Well-suited to research into GI health and reducing gut inflammation, this innovative blend may also have systemic healing effects.

Information on BPC-157 Injections

Although more definitive studies into the administration of BPC-157 in humans are needed, researchers may benefit from known clinical findings to guide safe and proper handling. When it comes to ordering BPC-157 injections, there is slightly more data to pull from. This is fortunate, due to the invasive nature of this delivery method.

Here, we will briefly cover routine considerations for researchers considering BPC-157 application via injection.

Administration and Dosage

Although subcutaneous injections are utilized, intramuscular is observed to be the most efficient. It is advised to begin with a low dose and increase incrementally. A widely observed daily dose is 250mcg, or 2-4mcg per kg. Many studies involve dosage cycles, which vary with the therapeutic target. Researchers are advised to consult all relevant literature for guidelines on the exact courses of therapy.

Reconstitution

Most peptides are available as lyophilized powders and must be reconstituted with a sterile solvent to be injected. Experts recommend the use of bacteriostatic water for this purpose. Composed of a natural preservative and sterile water, bacteriostatic water reduces the risk of contamination, extends the shelf life of solutions, and efficiently dissolves peptides while maintaining their purity levels. Additional materials are required for safe reconstitution and injection, available at the link provided.

No matter which route of administration is used, it is imperative to source BPC-157 from a legitimate supplier of quality peptides.

Click here to learn more about BPC-157 protocol and dosing.

Where to Buy BPC-157 Online? | 2024 Edition

Peptide quality is key for both safety and success in research. As such, we have combed the net for the best suppliers of research-only BPC-157 nasal sprays, capsules, and injectables.

When it comes to BPC-157 nasal spray, researchers should check out this high-quality offering from Limitless Life, a leading research peptide brand and a favorite here at Peptides.org.

This vendor verifies peptide purity with third-party Certificates of Analysis (CoAs) and offers rapid international shipping on top-quality items.

Let's take a look at more of their offerings below:

Limitless Life BPC-157/TB-500 Nasal Spray (10mg + 50mg)

This is by far the best BPC-157 nasal spray available on the market. By far.

Offering 10mg of BPC-157 and 50mg of TB-500, this potent and powerful nasal spray is designed to actually get results. With enough BPC-157 and TB-500 to actual offer healing in research settings, we can't recommend this research peptide spray enough.

Limitless Life BPC-157/TB-500 nasal spray is also the only formulation we've seen with sufficient quantity of each peptide to offer a legitimate alternative to aliquot BPC-157/TB-500.

Nothing else comes close!

Limitless Life BPC-157 Capsules

While we mentioned a few BPC-157 oral formulations above, some researchers might be interested in BPC-157 capsules that only include BPC-157 with no other peptides.

In this scenario, research should look no further than this great offering from our preferred peptide suppliers, Limitless Life. They offer a pure BPC-157 capsule peptide.

One bottle offers 60 capsules at 250 mcg per capsule.

Limitless Life BPC-157 10mg

And lastly, this company our go-to supplier of lab-tested injectable peptides, including BPC-157.

Why do we recommend Limitless Life these days? Because this company sticks to the highest standards of quality, with all their peptides and products being third-party verified.

As such, researchers receive only the highest quality peptides from Limitless Life, verified and trusted. Their 99%+ quality is considered of the highest quality. In comparison, 98.5% purity is said to be “pharmaceutical grade” by those in the know.

BPC-157 Benefits and Research Applications

The known benefits of BPC-157 are many, and ongoing studies are sure to add.

Here is a quick rundown of the most notable benefits of BPC-157 in current findings:

GI Function

In its natural element as a gastro peptide, BPC-157 contributes greatly to the structural integrity and function of the entire gastrointestinal tract. It is shown to fortify the gut lining while rapidly healing and protecting against lesions, also reducing inflammation and influencing global health by acting on the gut-brain axis. Human studies show its marked anti-ulcer effects and utility in the treatment of inflammatory bowel disease [2, 4, 33].

Improved Healing

Animal studies indicate that BPC-157 stimulates the proliferation of fibroblasts to enhance healing in many tissue types. These include the GI lining, as well as bones, skin, tendons, ligaments, and muscles [3, 33]

Angiogenesis

BPC-157 has been shown in animal models to increase angiogenesis through upregulating endothelial growth factor. This contributes to injury recovery and has the potential to boost cardiovascular health, increasing circulation and stabilizing blood pressure [33, 34, 35].

Neurological Health

BPC-157 is also evidenced to have neuroprotective effects, reducing nerve damage due to strokes and injuries while regulating neurotransmitters to attenuate symptoms of Parkinson’s disease, schizophrenia, and depression [2, 33, 36].

Treating Drug Toxicity

Similarly, BPC-157 effectively reduces the toxic effects of numerous drugs, including insulin, alcohol, NSAIDs, and neuroleptics. These protective benefits have been observed in the GI tract, liver, cardiovascular system, and brain [20, 36].

Powerful Anti-Inflammatory

Anti-inflammatory benefits have been evidenced with BPC-157 administration in many tissue types, including the lungs, liver, nervous system, and gastrointestinal tract [33, 34].

This is not an exhaustive list of the therapeutic effects observed in BPC-157. Emerging research further points to its anti-aging effects through collagen synthesis, as well as analgesic benefits [37, 38].

Is BPC-157 Safe?

Bearing in mind that there is a lack of data on BPC-157 use in humans, research suggests that it is safe and well-tolerated when properly handled. When adverse reactions have occurred, they have been mild and transient. These include [6, 34, 39]:

Irritation at the site of injection

Fatigue

Nausea

Light-headedness

Sweating

Adverse effects are often attributable to low-grade peptides. For this reason, peptides must be sourced from legitimate retailers. When handling BPC-157, researchers are encouraged to consult all relevant research and adhere to expert guidelines for safety and efficacy.

BPC-157 Nasal Spray | Verdict

In closing, intranasal administration represents a promising yet under-studied avenue of research into the therapeutic use of BPC-157.

However, a review of recent studies indicates that this is soon to change as more clinicians become aware of the unique advantages of nasal delivery of peptides and other therapeutics. These include targeted action on the central nervous system, excellent bioavailability, and the rapid onset of systemic effects. BPC-157 may be particularly suited to this route of administration due to its known neuroprotective benefits.

With great offerings such as the BPC-157 + TB-500 nasal spray from Limitless Life, researchers can seize the opportunity to conduct cutting-edge investigations into the great therapeutic potential of nasal BPC-157 administration.

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Dosing Protocols: What BPC-157 Studied Tennis Elbow Research Suggests

BPC-157 studied tennis elbow in animal models at doses ranging from 10–50 micrograms per kilogram body weight, administered daily via subcutaneous injection near the injury site. Translating this to a 70kg adult yields a dose range of 700–3,500 micrograms (0.7–3.5mg) daily. Most clinical observations report using 250–500 micrograms injected bilaterally. One injection proximal to the lateral epicondyle, one injection into the extensor mass itself. For 4–6 weeks. The peptide's half-life remains under-studied in humans but animal pharmacokinetics suggest elimination within 4–6 hours, which is why daily administration appears necessary. BPC-157 studied tennis elbow with both subcutaneous and intramuscular routes; subcutaneous injections 2–3cm from the injury site showed comparable efficacy to direct tendon injections in rat Achilles models, likely due to systemic circulation and local tissue uptake. Direct intra-tendon injection carries higher risk of mechanical disruption to already-damaged collagen fibers, which is why peri-tendinous subcutaneous placement is preferred. Reconstitution requires bacteriostatic water. Add 2mL to a 5mg vial for a 2.5mg/mL concentration, allowing precise measurement with insulin syringes. Store reconstituted peptide at 2–8°C and use within 28 days. Temperature excursions above 25°C for more than 6 hours denature the peptide structure, rendering it inactive. Our Healing Total Recovery Bundle includes detailed reconstitution guides and quality-contro…
SIDE EFFECTS

BPC-157 Side Effects, Risks, and Unknowns

When you look into BPC-157 side effects, this is what you’ll find: Research suggests that taking the peptide has potential risks, due to unregulated manufacturing and contamination, as well as a lack of clinical safety data on people. The fact that the risks are unknown is a huge part of the overall picture—and that’s sometimes disguised by sellers or influencers pointing to “successful” research. For example, you may hear about a 2025 pilot study (considered preliminary research), which found that BPC-157 infusions were well-tolerated with no side effects. But here’s the catch: This study was done on only two people, a 58-year-old man and a 68-year-old woman. BPC-157 is also not an FDA-approved treatment, and they've noted safety concerns surrounding this peptide, citing that it may contain impurities and may trigger an unwanted immune system response that could be dangerous. Because there's no safety data, the FDA says it may be harmful to people using it. The point is, we just don’t know, and there's so much more research that needs to be done. Beyond the lack of research on BPC-157, there are concerns over how people are accessing peptides in general. Gray-market peptides can create risks beyond the peptide itself, raising concerns over product quality, purity, and inconsistent formulation. In sum: Uncertain risks plus an unclear benefit equals a trade-off that’s just not worth it.
02

Question drills

Open a question for its connected answer.

01What If I'm Using BPC-157 Capsules Instead of Injectable—Do I Still Need Syringes?+

No. BPC-157 Capsules eliminate injection supplies entirely, but understand the bioavailability trade-off: oral BPC-157 undergoes first-pass hepatic metabolism and gastric protease degradation that reduces systemic absorption to 5-15% of the ingested dose compared to 85-95% for subcutaneous injection. Capsules work for localized gastric and intestinal applications where the peptide acts on mucosal tissue before absorption, but they're not equivalent to injection for systemic research applications. If your protocol targets connective tissue repair or systemic anti-inflammatory pathways, injectable BPC-157 with proper syringe supplies remains the evidence-based choice.

SOURCE / realpeptides.co ↗
02What If I've Already Had Rotator Cuff Surgery — Can BPC-157 Improve My Recovery?+

Post-surgical healing depends on collagen remodeling and tendon-to-bone integration. Both processes BPC-157 influences in animal models. Some patients use the peptide during the early post-op phase (weeks 2–8) to support fibroblast activity and reduce inflammatory cytokines that can delay healing. The challenge: no controlled trials exist to show whether this actually improves clinical outcomes like range of motion, strength, or re-tear rates. The peptide won't replace physical therapy, which is the proven determinant of post-surgical success. If you're considering BPC-157 post-surgery, discuss timing and dosing with your surgeon. Some prefer no adjunct therapies during the critical first 6 weeks.

SOURCE / realpeptides.co ↗
03What If the Peptide I Receive Doesn't Match Research-Grade Specifications?+

BPC-157 is sold by numerous suppliers without third-party purity verification. Research-grade peptides require HPLC (high-performance liquid chromatography) purity testing and mass spectrometry confirmation of amino-acid sequence. Peptides below 98% purity contain manufacturing byproducts that can trigger immune responses or compete for receptor binding. Real Peptides provides batch-specific HPLC certificates with every order. The verification standard necessary for reproducible research outcomes.

SOURCE / realpeptides.co ↗
04What If I Don't See Improvement After 4 Weeks on the BPC-157 50s Age Specific Protocol?+

Extend the cycle to 6–8 weeks before concluding non-response. Chronic tendinopathy and degenerative ligament issues require sustained signaling for collagen remodeling to manifest as functional improvement. Stopping at week 4 often precedes the visible response window by 1–2 weeks. If no improvement appears by week 6, reassess injection site accuracy (are you injecting within 2–3 cm of the actual injury?), verify peptide storage and reconstitution technique (degraded peptide loses efficacy), and consider whether the underlying issue is purely structural (advanced cartilage loss or full-thickness tendon tear may require surgical intervention rather than peptide support).

SOURCE / realpeptides.co ↗
05What If I'm Using Lower Doses (150mcg BPC-157, 100mcg LL-37) — Does Timing Still Matter as Much?+

Yes. Timing determines pathway sequencing regardless of dose magnitude. Lower doses reduce the absolute magnitude of each peptide's effect, but they don't change the fact that LL-37's immune modulation requires BPC-157's vascular scaffolding to reach its full potential. At lower doses, the risk of receptor competition at the injection site decreases, but the 60–90 minute interval still allows BPC-157's effects to establish before LL-37 peaks. If anything, lower doses make timing precision more critical because the margin for wasted peptide is smaller.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

BPC-157 in the Broader Tissue Repair Research Landscape

BPC-157 occupies a central position in the tissue-repair peptide research landscape. Its broad documented effects across gastrointestinal, tendon, ligament, and muscle tissue research, combined with its distinctive gastric stability, make it one of the most-studied research peptides. The compound features in numerous combination research protocols, including the widely studied BPC-157 + TB-500 pairing. For researchers interested in combination approaches, the BPC-157 TB-500 blend research overview covers the tissue-repair combination, and the GLOW and KLOW blends incorporate BPC-157 alongside complementary compounds for skin and tissue research. The throat spray format adds a local oral-mucosal delivery option to BPC-157’s already broad research delivery toolkit.

RESEARCH

BPC-157 Studied Stomach Ulcers — Mechanisms & Evidence

Most peptides marketed for gut health show underwhelming clinical evidence. But BPC-157 studied stomach ulcers is different. Preclinical research from the University of Zagreb demonstrated complete gastric ulcer healing in rodent models within 7–10 days, a timeline that outpaces standard H2 blockers like ranitidine by 40–60%. The mechanism isn't antacid suppression. BPC-157 upregulates vascular endothelial growth factor (VEGF) and modulates nitric oxide synthesis, directly accelerating angiogenesis and mucosal barrier reconstruction. Those aren't marketing claims. They're published findings from peer-reviewed gastroenterology journals spanning three decades of controlled animal studies. Our team has reviewed this peptide across hundreds of research compounds evaluated for therapeutic potential. The pattern is clear: BPC-157's gastroprotective profile stands apart from most experimental peptides because the mechanism targets tissue repair, not symptom masking. What makes BPC-157 effective for stomach ulcers? BPC-157 accelerates gastric ulcer healing through VEGF-driven angiogenesis, nitric oxide pathway modulation, and direct cytoprotective effects on mucosal epithelium. Studies published in the Journal of Physiology Paris showed that BPC-157 administration reduced ulcer area by 80–90% within one week in ethanol-induced and NSAID-induced ulcer models. The peptide enhances blood flow to damaged tissue, stabilizes the gastric mucosa against oxidative stress, and counteracts ulcer formation caused by both aspirin and corticosteroids in controlled trials.

05

Product & matchup locker

Linked catalog and comparison files.

Comparison

Comparison Table: Storage Methods and Their Impact

To make it crystal clear, here’s a breakdown of different storage scenarios and their outcomes. Room Temperature Shelf 20-25°C+ (68-77°F+) Catastrophic. Rapid degradation within h…

Comparison

BPC-157 ARA-290 Protocol Neuropathy Research: Clinical Trial Outcomes Comparison

Diabetic neuropathy pilot (2014, Molecular Medicine) ARA-290 monotherapy Type 2 diabetics with confirmed small fiber neuropathy Change in neuropathic pain scores (NPS) at 28 days …